Dimitrijević, Bogomir B.

Link to this page

Authority KeyName Variants
orcid::0000-0003-4775-6430
  • Dimitrijević, Bogomir B. (43)
Projects

Author's Bibliography

Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Demajo, Miroslav; Mandušić, Vesna; Dimitrijević, Bogomir B.

(2016)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Demajo, Miroslav
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1327
AB  - We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.
T2  - Personalized Medicine
T1  - Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue
VL  - 13
IS  - 6
SP  - 523
EP  - 530
DO  - 10.2217/pme-2016-0032
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Demajo, Miroslav and Mandušić, Vesna and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.",
journal = "Personalized Medicine",
title = "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue",
volume = "13",
number = "6",
pages = "523-530",
doi = "10.2217/pme-2016-0032"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Demajo, M., Mandušić, V.,& Dimitrijević, B. B.. (2016). Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine, 13(6), 523-530.
https://doi.org/10.2217/pme-2016-0032
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Demajo M, Mandušić V, Dimitrijević BB. Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine. 2016;13(6):523-530.
doi:10.2217/pme-2016-0032 .
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Demajo, Miroslav, Mandušić, Vesna, Dimitrijević, Bogomir B., "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue" in Personalized Medicine, 13, no. 6 (2016):523-530,
https://doi.org/10.2217/pme-2016-0032 . .
1
1
1
1

Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics

Krajnović, Milena M.; Markovic, Bojana; Knežević-Ušaj, Slavica; Nikolic, Ivan; Stanojevic, Maja; Nikolić, Valentina; Siljic, Marina; Jovanović-Ćupić, Snežana P.; Dimitrijević, Bogomir B.

(2016)

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Markovic, Bojana
AU  - Knežević-Ušaj, Slavica
AU  - Nikolic, Ivan
AU  - Stanojevic, Maja
AU  - Nikolić, Valentina
AU  - Siljic, Marina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1164
AB  - In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.
T2  - Pathology Research and Practice
T1  - Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
VL  - 212
IS  - 7
SP  - 598
EP  - 603
DO  - 10.1016/j.prp.2016.02.018
ER  - 
@article{
author = "Krajnović, Milena M. and Markovic, Bojana and Knežević-Ušaj, Slavica and Nikolic, Ivan and Stanojevic, Maja and Nikolić, Valentina and Siljic, Marina and Jovanović-Ćupić, Snežana P. and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.",
journal = "Pathology Research and Practice",
title = "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics",
volume = "212",
number = "7",
pages = "598-603",
doi = "10.1016/j.prp.2016.02.018"
}
Krajnović, M. M., Markovic, B., Knežević-Ušaj, S., Nikolic, I., Stanojevic, M., Nikolić, V., Siljic, M., Jovanović-Ćupić, S. P.,& Dimitrijević, B. B.. (2016). Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice, 212(7), 598-603.
https://doi.org/10.1016/j.prp.2016.02.018
Krajnović MM, Markovic B, Knežević-Ušaj S, Nikolic I, Stanojevic M, Nikolić V, Siljic M, Jovanović-Ćupić SP, Dimitrijević BB. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice. 2016;212(7):598-603.
doi:10.1016/j.prp.2016.02.018 .
Krajnović, Milena M., Markovic, Bojana, Knežević-Ušaj, Slavica, Nikolic, Ivan, Stanojevic, Maja, Nikolić, Valentina, Siljic, Marina, Jovanović-Ćupić, Snežana P., Dimitrijević, Bogomir B., "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics" in Pathology Research and Practice, 212, no. 7 (2016):598-603,
https://doi.org/10.1016/j.prp.2016.02.018 . .
1
9
9
8

Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia

Petrović, Nina; Mandušić, Vesna; Dimitrijević, Bogomir B.; Roganović, Jelena; Lukić, Silvana; Todorović, Lidija; Stanojević, Boban

(2014)

TY  - JOUR
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Roganović, Jelena
AU  - Lukić, Silvana
AU  - Todorović, Lidija
AU  - Stanojević, Boban
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6070
AB  - MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC-IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC-IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER? and PR? showed higher miR-21 levels than their negative receptor status paired groups ER-and PR-with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, rho = 0.379 and p = 0.034, rho = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.
T2  - Medical Oncology
T1  - Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia
VL  - 31
IS  - 6
DO  - 10.1007/s12032-014-0977-5
ER  - 
@article{
author = "Petrović, Nina and Mandušić, Vesna and Dimitrijević, Bogomir B. and Roganović, Jelena and Lukić, Silvana and Todorović, Lidija and Stanojević, Boban",
year = "2014",
abstract = "MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC-IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC-IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER? and PR? showed higher miR-21 levels than their negative receptor status paired groups ER-and PR-with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, rho = 0.379 and p = 0.034, rho = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.",
journal = "Medical Oncology",
title = "Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia",
volume = "31",
number = "6",
doi = "10.1007/s12032-014-0977-5"
}
Petrović, N., Mandušić, V., Dimitrijević, B. B., Roganović, J., Lukić, S., Todorović, L.,& Stanojević, B.. (2014). Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia. in Medical Oncology, 31(6).
https://doi.org/10.1007/s12032-014-0977-5
Petrović N, Mandušić V, Dimitrijević BB, Roganović J, Lukić S, Todorović L, Stanojević B. Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia. in Medical Oncology. 2014;31(6).
doi:10.1007/s12032-014-0977-5 .
Petrović, Nina, Mandušić, Vesna, Dimitrijević, Bogomir B., Roganović, Jelena, Lukić, Silvana, Todorović, Lidija, Stanojević, Boban, "Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia" in Medical Oncology, 31, no. 6 (2014),
https://doi.org/10.1007/s12032-014-0977-5 . .
9
13
11

The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion

Petrović, Nina; Mandušić, Vesna; Stanojević, Boban; Lukić, Silvana; Todorović, Lidija; Roganović, Jelena; Dimitrijević, Bogomir B.

(2014)

TY  - JOUR
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Stanojević, Boban
AU  - Lukić, Silvana
AU  - Todorović, Lidija
AU  - Roganović, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6041
AB  - MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.
T2  - Medical Oncology
T1  - The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion
VL  - 31
IS  - 3
DO  - 10.1007/s12032-014-0867-x
ER  - 
@article{
author = "Petrović, Nina and Mandušić, Vesna and Stanojević, Boban and Lukić, Silvana and Todorović, Lidija and Roganović, Jelena and Dimitrijević, Bogomir B.",
year = "2014",
abstract = "MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.",
journal = "Medical Oncology",
title = "The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion",
volume = "31",
number = "3",
doi = "10.1007/s12032-014-0867-x"
}
Petrović, N., Mandušić, V., Stanojević, B., Lukić, S., Todorović, L., Roganović, J.,& Dimitrijević, B. B.. (2014). The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. in Medical Oncology, 31(3).
https://doi.org/10.1007/s12032-014-0867-x
Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, Dimitrijević BB. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. in Medical Oncology. 2014;31(3).
doi:10.1007/s12032-014-0867-x .
Petrović, Nina, Mandušić, Vesna, Stanojević, Boban, Lukić, Silvana, Todorović, Lidija, Roganović, Jelena, Dimitrijević, Bogomir B., "The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion" in Medical Oncology, 31, no. 3 (2014),
https://doi.org/10.1007/s12032-014-0867-x . .
1
37
28
41

Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b

Jovanović-Ćupić, Snežana P.; Glišić, Sanja; Stanojevic, M.; Vasiljevic, N.; Bojić, Tijana; Božović, Ana M.; Dimitrijević, Bogomir B.

(2014)

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, M.
AU  - Vasiljevic, N.
AU  - Bojić, Tijana
AU  - Božović, Ana M.
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5858
AB  - Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.
T2  - Archives of biological sciences
T1  - Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b
VL  - 66
IS  - 1
SP  - 193
EP  - 201
DO  - 10.2298/ABS1401193J
ER  - 
@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, M. and Vasiljevic, N. and Bojić, Tijana and Božović, Ana M. and Dimitrijević, Bogomir B.",
year = "2014",
abstract = "Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.",
journal = "Archives of biological sciences",
title = "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b",
volume = "66",
number = "1",
pages = "193-201",
doi = "10.2298/ABS1401193J"
}
Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Vasiljevic, N., Bojić, T., Božović, A. M.,& Dimitrijević, B. B.. (2014). Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of biological sciences, 66(1), 193-201.
https://doi.org/10.2298/ABS1401193J
Jovanović-Ćupić SP, Glišić S, Stanojevic M, Vasiljevic N, Bojić T, Božović AM, Dimitrijević BB. Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of biological sciences. 2014;66(1):193-201.
doi:10.2298/ABS1401193J .
Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, M., Vasiljevic, N., Bojić, Tijana, Božović, Ana M., Dimitrijević, Bogomir B., "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b" in Archives of biological sciences, 66, no. 1 (2014):193-201,
https://doi.org/10.2298/ABS1401193J . .
2

Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer

Božović, Ana M.; Markicevic, Milan; Dimitrijević, Bogomir B.; Jovanović-Ćupić, Snežana P.; Krajnović, Milena M.; Lukić, Silvana; Mandušić, Vesna

(2013)

TY  - JOUR
AU  - Božović, Ana M.
AU  - Markicevic, Milan
AU  - Dimitrijević, Bogomir B.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
AU  - Lukić, Silvana
AU  - Mandušić, Vesna
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5647
AB  - The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.
T2  - Medical Oncology
T1  - Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0642-4
ER  - 
@article{
author = "Božović, Ana M. and Markicevic, Milan and Dimitrijević, Bogomir B. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M. and Lukić, Silvana and Mandušić, Vesna",
year = "2013",
abstract = "The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.",
journal = "Medical Oncology",
title = "Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0642-4"
}
Božović, A. M., Markicevic, M., Dimitrijević, B. B., Jovanović-Ćupić, S. P., Krajnović, M. M., Lukić, S.,& Mandušić, V.. (2013). Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer. in Medical Oncology, 30(3).
https://doi.org/10.1007/s12032-013-0642-4
Božović AM, Markicevic M, Dimitrijević BB, Jovanović-Ćupić SP, Krajnović MM, Lukić S, Mandušić V. Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer. in Medical Oncology. 2013;30(3).
doi:10.1007/s12032-013-0642-4 .
Božović, Ana M., Markicevic, Milan, Dimitrijević, Bogomir B., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., Lukić, Silvana, Mandušić, Vesna, "Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer" in Medical Oncology, 30, no. 3 (2013),
https://doi.org/10.1007/s12032-013-0642-4 . .
4
5
5

Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma

Krajnović, Milena M.; Radojkovic, Milica; Davidović, Radoslav S.; Dimitrijević, Bogomir B.; Krtolica-Žikić, Koviljka

(2013)

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Radojkovic, Milica
AU  - Davidović, Radoslav S.
AU  - Dimitrijević, Bogomir B.
AU  - Krtolica-Žikić, Koviljka
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5388
AB  - In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promotermethylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence.
T2  - Medical Oncology
T1  - Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma
VL  - 30
IS  - 1
DO  - 10.1007/s12032-012-0441-3
ER  - 
@article{
author = "Krajnović, Milena M. and Radojkovic, Milica and Davidović, Radoslav S. and Dimitrijević, Bogomir B. and Krtolica-Žikić, Koviljka",
year = "2013",
abstract = "In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promotermethylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence.",
journal = "Medical Oncology",
title = "Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma",
volume = "30",
number = "1",
doi = "10.1007/s12032-012-0441-3"
}
Krajnović, M. M., Radojkovic, M., Davidović, R. S., Dimitrijević, B. B.,& Krtolica-Žikić, K.. (2013). Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. in Medical Oncology, 30(1).
https://doi.org/10.1007/s12032-012-0441-3
Krajnović MM, Radojkovic M, Davidović RS, Dimitrijević BB, Krtolica-Žikić K. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. in Medical Oncology. 2013;30(1).
doi:10.1007/s12032-012-0441-3 .
Krajnović, Milena M., Radojkovic, Milica, Davidović, Radoslav S., Dimitrijević, Bogomir B., Krtolica-Žikić, Koviljka, "Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma" in Medical Oncology, 30, no. 1 (2013),
https://doi.org/10.1007/s12032-012-0441-3 . .
19
15
14

p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma

Davidović, Radoslav S.; Sopta, Jelena; Mandušić, Vesna; Krajnović, Milena M.; Stanojevic, Maja; Tulic, Goran; Dimitrijević, Bogomir B.

(2013)

TY  - JOUR
AU  - Davidović, Radoslav S.
AU  - Sopta, Jelena
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
AU  - Stanojevic, Maja
AU  - Tulic, Goran
AU  - Dimitrijević, Bogomir B.
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5646
AB  - Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.
T2  - Medical Oncology
T1  - p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0682-9
ER  - 
@article{
author = "Davidović, Radoslav S. and Sopta, Jelena and Mandušić, Vesna and Krajnović, Milena M. and Stanojevic, Maja and Tulic, Goran and Dimitrijević, Bogomir B.",
year = "2013",
abstract = "Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.",
journal = "Medical Oncology",
title = "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0682-9"
}
Davidović, R. S., Sopta, J., Mandušić, V., Krajnović, M. M., Stanojevic, M., Tulic, G.,& Dimitrijević, B. B.. (2013). p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology, 30(3).
https://doi.org/10.1007/s12032-013-0682-9
Davidović RS, Sopta J, Mandušić V, Krajnović MM, Stanojevic M, Tulic G, Dimitrijević BB. p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology. 2013;30(3).
doi:10.1007/s12032-013-0682-9 .
Davidović, Radoslav S., Sopta, Jelena, Mandušić, Vesna, Krajnović, Milena M., Stanojevic, Maja, Tulic, Goran, Dimitrijević, Bogomir B., "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma" in Medical Oncology, 30, no. 3 (2013),
https://doi.org/10.1007/s12032-013-0682-9 . .
7
4
5

Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells

Kurtovic, Nada Kraguljac; Krajnović, Milena M.; Bogdanović, Andrija; Suvajdzic, Nada; Jovanović, Jelica; Dimitrijević, Bogomir B.; Čolović, Milica; Krtolica-Žikić, Koviljka

(2012)

TY  - JOUR
AU  - Kurtovic, Nada Kraguljac
AU  - Krajnović, Milena M.
AU  - Bogdanović, Andrija
AU  - Suvajdzic, Nada
AU  - Jovanović, Jelica
AU  - Dimitrijević, Bogomir B.
AU  - Čolović, Milica
AU  - Krtolica-Žikić, Koviljka
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5173
AB  - In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117(+)/CD7(+)/CD34(+)/CD15(-)), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis.
T2  - Medical Oncology
T1  - Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells
VL  - 29
IS  - 5
SP  - 3547
EP  - 3556
DO  - 10.1007/s12032-012-0289-6
ER  - 
@article{
author = "Kurtovic, Nada Kraguljac and Krajnović, Milena M. and Bogdanović, Andrija and Suvajdzic, Nada and Jovanović, Jelica and Dimitrijević, Bogomir B. and Čolović, Milica and Krtolica-Žikić, Koviljka",
year = "2012",
abstract = "In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117(+)/CD7(+)/CD34(+)/CD15(-)), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis.",
journal = "Medical Oncology",
title = "Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells",
volume = "29",
number = "5",
pages = "3547-3556",
doi = "10.1007/s12032-012-0289-6"
}
Kurtovic, N. K., Krajnović, M. M., Bogdanović, A., Suvajdzic, N., Jovanović, J., Dimitrijević, B. B., Čolović, M.,& Krtolica-Žikić, K.. (2012). Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. in Medical Oncology, 29(5), 3547-3556.
https://doi.org/10.1007/s12032-012-0289-6
Kurtovic NK, Krajnović MM, Bogdanović A, Suvajdzic N, Jovanović J, Dimitrijević BB, Čolović M, Krtolica-Žikić K. Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. in Medical Oncology. 2012;29(5):3547-3556.
doi:10.1007/s12032-012-0289-6 .
Kurtovic, Nada Kraguljac, Krajnović, Milena M., Bogdanović, Andrija, Suvajdzic, Nada, Jovanović, Jelica, Dimitrijević, Bogomir B., Čolović, Milica, Krtolica-Žikić, Koviljka, "Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells" in Medical Oncology, 29, no. 5 (2012):3547-3556,
https://doi.org/10.1007/s12032-012-0289-6 . .
8
9
10

Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report

Stanojević, Boban; Dzodic, Radan; Saenko, Vladimir; Milovanović, Zorka M.; Krstevski, Vesna; Radlovic, Petar; Buta, Marko; Rulic, Bozidar; Todorović, Lidija; Dimitrijević, Bogomir B.; Yamashita, Shunichi

(2012)

TY  - JOUR
AU  - Stanojević, Boban
AU  - Dzodic, Radan
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Krstevski, Vesna
AU  - Radlovic, Petar
AU  - Buta, Marko
AU  - Rulic, Bozidar
AU  - Todorović, Lidija
AU  - Dimitrijević, Bogomir B.
AU  - Yamashita, Shunichi
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4970
AB  - Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.
T2  - BMC Cancer
T1  - Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report
VL  - 12
DO  - 10.1186/1471-2407-12-224
ER  - 
@article{
author = "Stanojević, Boban and Dzodic, Radan and Saenko, Vladimir and Milovanović, Zorka M. and Krstevski, Vesna and Radlovic, Petar and Buta, Marko and Rulic, Bozidar and Todorović, Lidija and Dimitrijević, Bogomir B. and Yamashita, Shunichi",
year = "2012",
abstract = "Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.",
journal = "BMC Cancer",
title = "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report",
volume = "12",
doi = "10.1186/1471-2407-12-224"
}
Stanojević, B., Dzodic, R., Saenko, V., Milovanović, Z. M., Krstevski, V., Radlovic, P., Buta, M., Rulic, B., Todorović, L., Dimitrijević, B. B.,& Yamashita, S.. (2012). Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer, 12.
https://doi.org/10.1186/1471-2407-12-224
Stanojević B, Dzodic R, Saenko V, Milovanović ZM, Krstevski V, Radlovic P, Buta M, Rulic B, Todorović L, Dimitrijević BB, Yamashita S. Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer. 2012;12.
doi:10.1186/1471-2407-12-224 .
Stanojević, Boban, Dzodic, Radan, Saenko, Vladimir, Milovanović, Zorka M., Krstevski, Vesna, Radlovic, Petar, Buta, Marko, Rulic, Bozidar, Todorović, Lidija, Dimitrijević, Bogomir B., Yamashita, Shunichi, "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report" in BMC Cancer, 12 (2012),
https://doi.org/10.1186/1471-2407-12-224 . .
1
16
16
16

Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer

Mandušić, Vesna; Dimitrijević, Bogomir B.; Nikolic-Vukosavljevic, Dragica; Nešković-Konstantinović, Zora; Kanjer, Ksenija; Hamann, Ute

(2012)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Kanjer, Ksenija
AU  - Hamann, Ute
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5002
AB  - Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
T2  - Cancer Letters
T1  - Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer
VL  - 321
IS  - 1
SP  - 73
EP  - 79
DO  - 10.1016/j.canlet.2012.02.022
ER  - 
@article{
author = "Mandušić, Vesna and Dimitrijević, Bogomir B. and Nikolic-Vukosavljevic, Dragica and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Hamann, Ute",
year = "2012",
abstract = "Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.",
journal = "Cancer Letters",
title = "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer",
volume = "321",
number = "1",
pages = "73-79",
doi = "10.1016/j.canlet.2012.02.022"
}
Mandušić, V., Dimitrijević, B. B., Nikolic-Vukosavljevic, D., Nešković-Konstantinović, Z., Kanjer, K.,& Hamann, U.. (2012). Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters, 321(1), 73-79.
https://doi.org/10.1016/j.canlet.2012.02.022
Mandušić V, Dimitrijević BB, Nikolic-Vukosavljevic D, Nešković-Konstantinović Z, Kanjer K, Hamann U. Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters. 2012;321(1):73-79.
doi:10.1016/j.canlet.2012.02.022 .
Mandušić, Vesna, Dimitrijević, Bogomir B., Nikolic-Vukosavljevic, Dragica, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Hamann, Ute, "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer" in Cancer Letters, 321, no. 1 (2012):73-79,
https://doi.org/10.1016/j.canlet.2012.02.022 . .
10
7
12

The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients

Tanić, Nikola; Milovanović, Zorka M.; Tanić, Nasta; Dzodic, Radan; Juranic, Zorica; Šušnjar, Snežana; Plesinac-Karapandzic, Vesna; Tatic, Svetislav; Dramićanin, Tatjana; Davidović, Radoslav S.; Dimitrijević, Bogomir B.

(2012)

TY  - JOUR
AU  - Tanić, Nikola
AU  - Milovanović, Zorka M.
AU  - Tanić, Nasta
AU  - Dzodic, Radan
AU  - Juranic, Zorica
AU  - Šušnjar, Snežana
AU  - Plesinac-Karapandzic, Vesna
AU  - Tatic, Svetislav
AU  - Dramićanin, Tatjana
AU  - Davidović, Radoslav S.
AU  - Dimitrijević, Bogomir B.
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5073
AB  - Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.
T2  - Cancer Biology and Therapy
T1  - The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients
VL  - 13
IS  - 12
SP  - 1165
EP  - 1174
DO  - 10.4161/cbt.21346
ER  - 
@article{
author = "Tanić, Nikola and Milovanović, Zorka M. and Tanić, Nasta and Dzodic, Radan and Juranic, Zorica and Šušnjar, Snežana and Plesinac-Karapandzic, Vesna and Tatic, Svetislav and Dramićanin, Tatjana and Davidović, Radoslav S. and Dimitrijević, Bogomir B.",
year = "2012",
abstract = "Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.",
journal = "Cancer Biology and Therapy",
title = "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients",
volume = "13",
number = "12",
pages = "1165-1174",
doi = "10.4161/cbt.21346"
}
Tanić, N., Milovanović, Z. M., Tanić, N., Dzodic, R., Juranic, Z., Šušnjar, S., Plesinac-Karapandzic, V., Tatic, S., Dramićanin, T., Davidović, R. S.,& Dimitrijević, B. B.. (2012). The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy, 13(12), 1165-1174.
https://doi.org/10.4161/cbt.21346
Tanić N, Milovanović ZM, Tanić N, Dzodic R, Juranic Z, Šušnjar S, Plesinac-Karapandzic V, Tatic S, Dramićanin T, Davidović RS, Dimitrijević BB. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy. 2012;13(12):1165-1174.
doi:10.4161/cbt.21346 .
Tanić, Nikola, Milovanović, Zorka M., Tanić, Nasta, Dzodic, Radan, Juranic, Zorica, Šušnjar, Snežana, Plesinac-Karapandzic, Vesna, Tatic, Svetislav, Dramićanin, Tatjana, Davidović, Radoslav S., Dimitrijević, Bogomir B., "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients" in Cancer Biology and Therapy, 13, no. 12 (2012):1165-1174,
https://doi.org/10.4161/cbt.21346 . .
28
24
32

Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy

Dramićanin, Tatjana; Dimitrijević, Bogomir B.; Dramićanin, Miroslav

(2011)

TY  - JOUR
AU  - Dramićanin, Tatjana
AU  - Dimitrijević, Bogomir B.
AU  - Dramićanin, Miroslav
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4235
AB  - Data from total synchronous fluorescence spectroscopy (TSFS) measurements of normal and malignant breast tissue samples are introduced in supervised self-organizing maps, a type of artificial neural network (ANN), to obtain diagnosis. Three spectral regions in both TSFS patterns and first-derivative TSFS patterns exhibited clear differences between normal and malignant tissue groups, and intensities measured from these regions served as inputs to neural networks. Histology findings are used as the gold standard to train self-organizing maps in a supervised way. Diagnostic accuracy of this procedure is evaluated with sample test groups for two cases, when the neural network uses TSFS data and when the neural network uses data from first-derivative TSFS. In the first case diagnostic sensitivity of 87.1% and specificity of 91.7% are found, while in the second case sensitivity of 100% and specificity of 94.4% are achieved.
T2  - Applied Spectroscopy
T1  - Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy
VL  - 65
IS  - 3
SP  - 293
EP  - 297
DO  - 10.1366/10-05928
ER  - 
@article{
author = "Dramićanin, Tatjana and Dimitrijević, Bogomir B. and Dramićanin, Miroslav",
year = "2011",
abstract = "Data from total synchronous fluorescence spectroscopy (TSFS) measurements of normal and malignant breast tissue samples are introduced in supervised self-organizing maps, a type of artificial neural network (ANN), to obtain diagnosis. Three spectral regions in both TSFS patterns and first-derivative TSFS patterns exhibited clear differences between normal and malignant tissue groups, and intensities measured from these regions served as inputs to neural networks. Histology findings are used as the gold standard to train self-organizing maps in a supervised way. Diagnostic accuracy of this procedure is evaluated with sample test groups for two cases, when the neural network uses TSFS data and when the neural network uses data from first-derivative TSFS. In the first case diagnostic sensitivity of 87.1% and specificity of 91.7% are found, while in the second case sensitivity of 100% and specificity of 94.4% are achieved.",
journal = "Applied Spectroscopy",
title = "Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy",
volume = "65",
number = "3",
pages = "293-297",
doi = "10.1366/10-05928"
}
Dramićanin, T., Dimitrijević, B. B.,& Dramićanin, M.. (2011). Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy. in Applied Spectroscopy, 65(3), 293-297.
https://doi.org/10.1366/10-05928
Dramićanin T, Dimitrijević BB, Dramićanin M. Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy. in Applied Spectroscopy. 2011;65(3):293-297.
doi:10.1366/10-05928 .
Dramićanin, Tatjana, Dimitrijević, Bogomir B., Dramićanin, Miroslav, "Application of Supervised Self-Organizing Maps in Breast Cancer Diagnosis by Total Synchronous Fluorescence Spectroscopy" in Applied Spectroscopy, 65, no. 3 (2011):293-297,
https://doi.org/10.1366/10-05928 . .
14
13
15

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia

Stanojević, Boban; Dzodic, Radan; Saenko, Vladimir; Milovanović, Zorka M.; Pupic, Gordana; Zivkovic, Ognjen; Markovic, Ivan; Đurišić, Igor; Buta, Marko; Dimitrijević, Bogomir B.; Rogounovitch, Tatiana; Mitsutake, Norisato; Mine, Mariko; Shibata, Yoshisada; Nakashima, Masahiro; Yamashita, Shunichi

(2011)

TY  - JOUR
AU  - Stanojević, Boban
AU  - Dzodic, Radan
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Pupic, Gordana
AU  - Zivkovic, Ognjen
AU  - Markovic, Ivan
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Dimitrijević, Bogomir B.
AU  - Rogounovitch, Tatiana
AU  - Mitsutake, Norisato
AU  - Mine, Mariko
AU  - Shibata, Yoshisada
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4401
AB  - Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.
T2  - Endocrine Journal
T1  - Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
VL  - 58
IS  - 5
SP  - 381
EP  - 393
DO  - 10.1507/endocrj.K11E-054
ER  - 
@article{
author = "Stanojević, Boban and Dzodic, Radan and Saenko, Vladimir and Milovanović, Zorka M. and Pupic, Gordana and Zivkovic, Ognjen and Markovic, Ivan and Đurišić, Igor and Buta, Marko and Dimitrijević, Bogomir B. and Rogounovitch, Tatiana and Mitsutake, Norisato and Mine, Mariko and Shibata, Yoshisada and Nakashima, Masahiro and Yamashita, Shunichi",
year = "2011",
abstract = "Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.",
journal = "Endocrine Journal",
title = "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia",
volume = "58",
number = "5",
pages = "381-393",
doi = "10.1507/endocrj.K11E-054"
}
Stanojević, B., Dzodic, R., Saenko, V., Milovanović, Z. M., Pupic, G., Zivkovic, O., Markovic, I., Đurišić, I., Buta, M., Dimitrijević, B. B., Rogounovitch, T., Mitsutake, N., Mine, M., Shibata, Y., Nakashima, M.,& Yamashita, S.. (2011). Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal, 58(5), 381-393.
https://doi.org/10.1507/endocrj.K11E-054
Stanojević B, Dzodic R, Saenko V, Milovanović ZM, Pupic G, Zivkovic O, Markovic I, Đurišić I, Buta M, Dimitrijević BB, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal. 2011;58(5):381-393.
doi:10.1507/endocrj.K11E-054 .
Stanojević, Boban, Dzodic, Radan, Saenko, Vladimir, Milovanović, Zorka M., Pupic, Gordana, Zivkovic, Ognjen, Markovic, Ivan, Đurišić, Igor, Buta, Marko, Dimitrijević, Bogomir B., Rogounovitch, Tatiana, Mitsutake, Norisato, Mine, Mariko, Shibata, Yoshisada, Nakashima, Masahiro, Yamashita, Shunichi, "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia" in Endocrine Journal, 58, no. 5 (2011):381-393,
https://doi.org/10.1507/endocrj.K11E-054 . .
30
28
31

Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study

Kurtovic, Nada Kraguljac; Krajnović, Milena M.; Dimitrijević, Bogomir B.; Mihaljevic, Biljana; Gotic, Mirjana; Krtolica-Žikić, Koviljka

(2010)

TY  - JOUR
AU  - Kurtovic, Nada Kraguljac
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Mihaljevic, Biljana
AU  - Gotic, Mirjana
AU  - Krtolica-Žikić, Koviljka
PY  - 2010
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4045
AB  - The methylation status of the target promoter sequences of p15(INK4B) (p15) and O-6-methylguanine-DNA methyltransferase (MGMT) genes was studied by methylation-specific PCR in 10 adult patients with de novo B-cell non-Hodgkin lymphoma (B-NHL). The aberrant hypermethylation of the p15 gene was more frequent (50%) compared to the hypermethylation of the MGMT gene (30%), and was detected in different types of B-NHL in both genes. Hypermethylation of the MGMT gene occurred exclusively in association with the hypermethylation of the p15 gene. All lymphoma patients with hypermethylation of the p15 and/or MGMT genes had a higher clinical stage of the disease (IV - V). We show the association of anemia and/or thrombocytopenia with the hypermethylation of the p15 gene, ascribing the p15 gene as a potential prognostic marker in B-NHL. Comethylation of MGMT with the p15 gene represents a novel finding and presents both genes as candidates for future studies of the hypermethylation profiles of B-NHL.
T2  - Archives of biological sciences
T1  - Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study
VL  - 62
IS  - 2
SP  - 211
EP  - 221
DO  - 10.2298/ABS1002211K
ER  - 
@article{
author = "Kurtovic, Nada Kraguljac and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Mihaljevic, Biljana and Gotic, Mirjana and Krtolica-Žikić, Koviljka",
year = "2010",
abstract = "The methylation status of the target promoter sequences of p15(INK4B) (p15) and O-6-methylguanine-DNA methyltransferase (MGMT) genes was studied by methylation-specific PCR in 10 adult patients with de novo B-cell non-Hodgkin lymphoma (B-NHL). The aberrant hypermethylation of the p15 gene was more frequent (50%) compared to the hypermethylation of the MGMT gene (30%), and was detected in different types of B-NHL in both genes. Hypermethylation of the MGMT gene occurred exclusively in association with the hypermethylation of the p15 gene. All lymphoma patients with hypermethylation of the p15 and/or MGMT genes had a higher clinical stage of the disease (IV - V). We show the association of anemia and/or thrombocytopenia with the hypermethylation of the p15 gene, ascribing the p15 gene as a potential prognostic marker in B-NHL. Comethylation of MGMT with the p15 gene represents a novel finding and presents both genes as candidates for future studies of the hypermethylation profiles of B-NHL.",
journal = "Archives of biological sciences",
title = "Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study",
volume = "62",
number = "2",
pages = "211-221",
doi = "10.2298/ABS1002211K"
}
Kurtovic, N. K., Krajnović, M. M., Dimitrijević, B. B., Mihaljevic, B., Gotic, M.,& Krtolica-Žikić, K.. (2010). Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study. in Archives of biological sciences, 62(2), 211-221.
https://doi.org/10.2298/ABS1002211K
Kurtovic NK, Krajnović MM, Dimitrijević BB, Mihaljevic B, Gotic M, Krtolica-Žikić K. Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study. in Archives of biological sciences. 2010;62(2):211-221.
doi:10.2298/ABS1002211K .
Kurtovic, Nada Kraguljac, Krajnović, Milena M., Dimitrijević, Bogomir B., Mihaljevic, Biljana, Gotic, Mirjana, Krtolica-Žikić, Koviljka, "Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study" in Archives of biological sciences, 62, no. 2 (2010):211-221,
https://doi.org/10.2298/ABS1002211K . .
3
3
3

Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Budisin, Nikola; Savovski, Kiril; Demajo, Miroslav; Dimitrijević, Bogomir B.

(2009)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Budisin, Nikola
AU  - Savovski, Kiril
AU  - Demajo, Miroslav
AU  - Dimitrijević, Bogomir B.
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2728
AB  - OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)
T2  - Analytical and Quantitative Cytology and Histology
T1  - Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source
VL  - 31
IS  - 5
SP  - 288
EP  - 295
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Budisin, Nikola and Savovski, Kiril and Demajo, Miroslav and Dimitrijević, Bogomir B.",
year = "2009",
abstract = "OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)",
journal = "Analytical and Quantitative Cytology and Histology",
title = "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source",
volume = "31",
number = "5",
pages = "288-295"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Budisin, N., Savovski, K., Demajo, M.,& Dimitrijević, B. B.. (2009). Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology, 31(5), 288-295.
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Budisin N, Savovski K, Demajo M, Dimitrijević BB. Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology. 2009;31(5):288-295..
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Budisin, Nikola, Savovski, Kiril, Demajo, Miroslav, Dimitrijević, Bogomir B., "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source" in Analytical and Quantitative Cytology and Histology, 31, no. 5 (2009):288-295.
4

Genomic instability and tumor-specific DNA alterations in oral leukoplakias

Tanić, Nikola; Tanić, Nikola; Milašin, Jelena; Vukadinovic, Miroslav; Dimitrijević, Bogomir B.

(2009)

TY  - JOUR
AU  - Tanić, Nikola
AU  - Tanić, Nikola
AU  - Milašin, Jelena
AU  - Vukadinovic, Miroslav
AU  - Dimitrijević, Bogomir B.
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3692
AB  - Leukoplakias, clinically identifiable premalignant lesions, often precede oral squamous cell carcinoma (OSCC). Identification of leukoplakias that have the potential for transformation to malignancy is a key clinical problem. The aim of this study was to assess genomic instability, and to detect tumor-specific genomic alterations, in leukoplakias. Genomic instability was analyzed by comparing the DNA fingerprints of 32 leukoplakias with those of paired normal tissue. In addition, the mutational status of the p53 gene was analyzed using polymerase chain reaction-single-stranded conformational polymorphism (PCR-SSCP) and polymerase chain reaction-heteroduplex DNA (PCR-HET), and the mutations were subsequently confirmed by DNA sequencing. Moderate-to-significant genomic instability was detected in all leukoplakias analysed. Nine unique amplicons, present in leukoplakias but not in normal tissue, were retrieved and successfully characterized. The p53 gene was mutated in 40.6% of patients. Four patients with moderate instability and mutated p53 developed OSCC. The data obtained in this study support and concretize the thesis that premalignant lesions possess many of the alterations found in cancer before the development of a malignant phenotype. Inactivation or mutation of the p53 tumor-suppressor might be an early event contributing to genomic instability and increasing the risk of malignant transformation.
T2  - European Journal of Oral Sciences
T1  - Genomic instability and tumor-specific DNA alterations in oral leukoplakias
VL  - 117
IS  - 3
SP  - 231
EP  - 237
DO  - 10.1111/j.1600-0722.2009.00624.x
ER  - 
@article{
author = "Tanić, Nikola and Tanić, Nikola and Milašin, Jelena and Vukadinovic, Miroslav and Dimitrijević, Bogomir B.",
year = "2009",
abstract = "Leukoplakias, clinically identifiable premalignant lesions, often precede oral squamous cell carcinoma (OSCC). Identification of leukoplakias that have the potential for transformation to malignancy is a key clinical problem. The aim of this study was to assess genomic instability, and to detect tumor-specific genomic alterations, in leukoplakias. Genomic instability was analyzed by comparing the DNA fingerprints of 32 leukoplakias with those of paired normal tissue. In addition, the mutational status of the p53 gene was analyzed using polymerase chain reaction-single-stranded conformational polymorphism (PCR-SSCP) and polymerase chain reaction-heteroduplex DNA (PCR-HET), and the mutations were subsequently confirmed by DNA sequencing. Moderate-to-significant genomic instability was detected in all leukoplakias analysed. Nine unique amplicons, present in leukoplakias but not in normal tissue, were retrieved and successfully characterized. The p53 gene was mutated in 40.6% of patients. Four patients with moderate instability and mutated p53 developed OSCC. The data obtained in this study support and concretize the thesis that premalignant lesions possess many of the alterations found in cancer before the development of a malignant phenotype. Inactivation or mutation of the p53 tumor-suppressor might be an early event contributing to genomic instability and increasing the risk of malignant transformation.",
journal = "European Journal of Oral Sciences",
title = "Genomic instability and tumor-specific DNA alterations in oral leukoplakias",
volume = "117",
number = "3",
pages = "231-237",
doi = "10.1111/j.1600-0722.2009.00624.x"
}
Tanić, N., Tanić, N., Milašin, J., Vukadinovic, M.,& Dimitrijević, B. B.. (2009). Genomic instability and tumor-specific DNA alterations in oral leukoplakias. in European Journal of Oral Sciences, 117(3), 231-237.
https://doi.org/10.1111/j.1600-0722.2009.00624.x
Tanić N, Tanić N, Milašin J, Vukadinovic M, Dimitrijević BB. Genomic instability and tumor-specific DNA alterations in oral leukoplakias. in European Journal of Oral Sciences. 2009;117(3):231-237.
doi:10.1111/j.1600-0722.2009.00624.x .
Tanić, Nikola, Tanić, Nikola, Milašin, Jelena, Vukadinovic, Miroslav, Dimitrijević, Bogomir B., "Genomic instability and tumor-specific DNA alterations in oral leukoplakias" in European Journal of Oral Sciences, 117, no. 3 (2009):231-237,
https://doi.org/10.1111/j.1600-0722.2009.00624.x . .
7
6
8

Concurrent quantitation of the A and D genotypes of hepatitis B virus

Tanić, Nikola; Stanojević, Boban; Tanić, Nikola; Schaefer, Stephan; Niesters, Hubert G. M.; Božić, Milena; Dimitrijević, Bogomir B.

(2009)

TY  - JOUR
AU  - Tanić, Nikola
AU  - Stanojević, Boban
AU  - Tanić, Nikola
AU  - Schaefer, Stephan
AU  - Niesters, Hubert G. M.
AU  - Božić, Milena
AU  - Dimitrijević, Bogomir B.
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3789
AB  - Hepatitis B virus (HBV) infection is a global health problem associated with severe liver disorders. Viral load and HBV genotype affect the clinical outcome, guide antiviral therapy and provide long term prognosis for HBV infected patients. Various types of detection and quantitation assays are currently in use with a different effectiveness. The aim of this study was to develop a method that would provide simultaneous identification and quantitation of genotypes A and D in a single-tube reaction. Sera from infected patients were analyzed by a TaqMan based real time PCR. Optimized reagents were used for HBV DNA quantitation while the genotypes A and D were quantified separately by our design of the assay. Multiplex real time PCR was achieved and was specific for HBV genotypes A and D within a single-tube reaction. Simulation of mixed virus populations was identified reproducibly in vitro. Quantitation of these individual genotypes was exceptionally reliable, so much so that the sum of individual genotypes was equal to the total viral load determined in a separate reaction. Therefore, a straightforward, conceptually simple and reliable approach to issues involving HBV genotypes A and D is submitted. Identity and exact titer of these genotypes in the Caucasian population can now be determined easily. (C) 2009 Elsevier B.V. All rights reserved.
T2  - Journal of Virological Methods
T1  - Concurrent quantitation of the A and D genotypes of hepatitis B virus
VL  - 161
IS  - 2
SP  - 265
EP  - 270
DO  - 10.1016/j.jviromet.2009.06.022
ER  - 
@article{
author = "Tanić, Nikola and Stanojević, Boban and Tanić, Nikola and Schaefer, Stephan and Niesters, Hubert G. M. and Božić, Milena and Dimitrijević, Bogomir B.",
year = "2009",
abstract = "Hepatitis B virus (HBV) infection is a global health problem associated with severe liver disorders. Viral load and HBV genotype affect the clinical outcome, guide antiviral therapy and provide long term prognosis for HBV infected patients. Various types of detection and quantitation assays are currently in use with a different effectiveness. The aim of this study was to develop a method that would provide simultaneous identification and quantitation of genotypes A and D in a single-tube reaction. Sera from infected patients were analyzed by a TaqMan based real time PCR. Optimized reagents were used for HBV DNA quantitation while the genotypes A and D were quantified separately by our design of the assay. Multiplex real time PCR was achieved and was specific for HBV genotypes A and D within a single-tube reaction. Simulation of mixed virus populations was identified reproducibly in vitro. Quantitation of these individual genotypes was exceptionally reliable, so much so that the sum of individual genotypes was equal to the total viral load determined in a separate reaction. Therefore, a straightforward, conceptually simple and reliable approach to issues involving HBV genotypes A and D is submitted. Identity and exact titer of these genotypes in the Caucasian population can now be determined easily. (C) 2009 Elsevier B.V. All rights reserved.",
journal = "Journal of Virological Methods",
title = "Concurrent quantitation of the A and D genotypes of hepatitis B virus",
volume = "161",
number = "2",
pages = "265-270",
doi = "10.1016/j.jviromet.2009.06.022"
}
Tanić, N., Stanojević, B., Tanić, N., Schaefer, S., Niesters, H. G. M., Božić, M.,& Dimitrijević, B. B.. (2009). Concurrent quantitation of the A and D genotypes of hepatitis B virus. in Journal of Virological Methods, 161(2), 265-270.
https://doi.org/10.1016/j.jviromet.2009.06.022
Tanić N, Stanojević B, Tanić N, Schaefer S, Niesters HGM, Božić M, Dimitrijević BB. Concurrent quantitation of the A and D genotypes of hepatitis B virus. in Journal of Virological Methods. 2009;161(2):265-270.
doi:10.1016/j.jviromet.2009.06.022 .
Tanić, Nikola, Stanojević, Boban, Tanić, Nikola, Schaefer, Stephan, Niesters, Hubert G. M., Božić, Milena, Dimitrijević, Bogomir B., "Concurrent quantitation of the A and D genotypes of hepatitis B virus" in Journal of Virological Methods, 161, no. 2 (2009):265-270,
https://doi.org/10.1016/j.jviromet.2009.06.022 . .
3
3
3

Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data

Dramićanin, Tatjana; Zeković, Ivana Lj.; Dimitrijević, Bogomir B.; Ribar, S.; Dramićanin, Miroslav

(2009)

TY  - JOUR
AU  - Dramićanin, Tatjana
AU  - Zeković, Ivana Lj.
AU  - Dimitrijević, Bogomir B.
AU  - Ribar, S.
AU  - Dramićanin, Miroslav
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6848
AB  - Supervised self-organizing map, a type of artificial neural network, is applied for classification of human breast tissue samples utilizing data obtained from fluorescence landscape measurements. Female breast tissue samples were taken soon after the surgical resection, identified and stored at -80 degrees C until fluorescence measurements. From fluorescence landscapes obtained in UV-VIS region spectral features showing statistically significant differences between malignant and normal samples are identified and further quantified to serve as a training input to neural network. Additional set of samples was used as a test group input to trained network in order to evaluate performance of proposed optical biopsy method. Classification sensitivity of 83.9% and specificity of 88.9% are found.
T2  - Acta Physica Polonica. Series A: General Physics, Physics of Condensed Matter, Optics and Quantum Electronics, Atomic and Molecular Physics, Applied Physics
T1  - Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data
VL  - 116
IS  - 4
SP  - 690
EP  - 692
DO  - 10.12693/APhysPolA.116.690
ER  - 
@article{
author = "Dramićanin, Tatjana and Zeković, Ivana Lj. and Dimitrijević, Bogomir B. and Ribar, S. and Dramićanin, Miroslav",
year = "2009",
abstract = "Supervised self-organizing map, a type of artificial neural network, is applied for classification of human breast tissue samples utilizing data obtained from fluorescence landscape measurements. Female breast tissue samples were taken soon after the surgical resection, identified and stored at -80 degrees C until fluorescence measurements. From fluorescence landscapes obtained in UV-VIS region spectral features showing statistically significant differences between malignant and normal samples are identified and further quantified to serve as a training input to neural network. Additional set of samples was used as a test group input to trained network in order to evaluate performance of proposed optical biopsy method. Classification sensitivity of 83.9% and specificity of 88.9% are found.",
journal = "Acta Physica Polonica. Series A: General Physics, Physics of Condensed Matter, Optics and Quantum Electronics, Atomic and Molecular Physics, Applied Physics",
title = "Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data",
volume = "116",
number = "4",
pages = "690-692",
doi = "10.12693/APhysPolA.116.690"
}
Dramićanin, T., Zeković, I. Lj., Dimitrijević, B. B., Ribar, S.,& Dramićanin, M.. (2009). Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data. in Acta Physica Polonica. Series A: General Physics, Physics of Condensed Matter, Optics and Quantum Electronics, Atomic and Molecular Physics, Applied Physics, 116(4), 690-692.
https://doi.org/10.12693/APhysPolA.116.690
Dramićanin T, Zeković IL, Dimitrijević BB, Ribar S, Dramićanin M. Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data. in Acta Physica Polonica. Series A: General Physics, Physics of Condensed Matter, Optics and Quantum Electronics, Atomic and Molecular Physics, Applied Physics. 2009;116(4):690-692.
doi:10.12693/APhysPolA.116.690 .
Dramićanin, Tatjana, Zeković, Ivana Lj., Dimitrijević, Bogomir B., Ribar, S., Dramićanin, Miroslav, "Optical Biopsy Method for Breast Cancer Diagnosis Based on Artificial Neural Network Classification of Fluorescence Landscape Data" in Acta Physica Polonica. Series A: General Physics, Physics of Condensed Matter, Optics and Quantum Electronics, Atomic and Molecular Physics, Applied Physics, 116, no. 4 (2009):690-692,
https://doi.org/10.12693/APhysPolA.116.690 . .
3
4
4

Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer

Mandušić, Vesna; Nikolic-Vukosavljevic, Dragica; Tanić, Nikola; Kanjer, Ksenija; Nešković-Konstantinović, Zora; Celeketic, Dusica; Dimitrijević, Bogomir B.

(2007)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Tanić, Nikola
AU  - Kanjer, Ksenija
AU  - Nešković-Konstantinović, Zora
AU  - Celeketic, Dusica
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2576
AB  - Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer
VL  - 133
IS  - 8
SP  - 571
EP  - 579
DO  - 10.1007/s00432-007-0209-x
ER  - 
@article{
author = "Mandušić, Vesna and Nikolic-Vukosavljevic, Dragica and Tanić, Nikola and Kanjer, Ksenija and Nešković-Konstantinović, Zora and Celeketic, Dusica and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer",
volume = "133",
number = "8",
pages = "571-579",
doi = "10.1007/s00432-007-0209-x"
}
Mandušić, V., Nikolic-Vukosavljevic, D., Tanić, N., Kanjer, K., Nešković-Konstantinović, Z., Celeketic, D.,& Dimitrijević, B. B.. (2007). Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology, 133(8), 571-579.
https://doi.org/10.1007/s00432-007-0209-x
Mandušić V, Nikolic-Vukosavljevic D, Tanić N, Kanjer K, Nešković-Konstantinović Z, Celeketic D, Dimitrijević BB. Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology. 2007;133(8):571-579.
doi:10.1007/s00432-007-0209-x .
Mandušić, Vesna, Nikolic-Vukosavljevic, Dragica, Tanić, Nikola, Kanjer, Ksenija, Nešković-Konstantinović, Zora, Celeketic, Dusica, Dimitrijević, Bogomir B., "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer" in Journal of Cancer Research and Clinical Oncology, 133, no. 8 (2007):571-579,
https://doi.org/10.1007/s00432-007-0209-x . .
3
15
15
21

Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value

Krtolica-Žikić, Koviljka; Krajnović, Milena M.; Usaj-Knežević, Slavica; Babić, Dragan; Jovanovic, Dusan; Dimitrijević, Bogomir B.

(2007)

TY  - JOUR
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Usaj-Knežević, Slavica
AU  - Babić, Dragan
AU  - Jovanovic, Dusan
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3184
AB  - AIM: To investigate the significance of p16 and O-6- methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS: p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS: p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCS, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectible occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P LT 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P LT 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P LT 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis. (C) 2007 The WJG Press. All rights reserved.
T2  - World Journal of Gastroenterology
T1  - Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value
VL  - 13
IS  - 8
SP  - 1187
EP  - 1194
DO  - 10.3748/wjg.v13.i8.1187
ER  - 
@article{
author = "Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Usaj-Knežević, Slavica and Babić, Dragan and Jovanovic, Dusan and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "AIM: To investigate the significance of p16 and O-6- methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS: p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS: p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCS, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectible occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P LT 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P LT 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P LT 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis. (C) 2007 The WJG Press. All rights reserved.",
journal = "World Journal of Gastroenterology",
title = "Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value",
volume = "13",
number = "8",
pages = "1187-1194",
doi = "10.3748/wjg.v13.i8.1187"
}
Krtolica-Žikić, K., Krajnović, M. M., Usaj-Knežević, S., Babić, D., Jovanovic, D.,& Dimitrijević, B. B.. (2007). Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. in World Journal of Gastroenterology, 13(8), 1187-1194.
https://doi.org/10.3748/wjg.v13.i8.1187
Krtolica-Žikić K, Krajnović MM, Usaj-Knežević S, Babić D, Jovanovic D, Dimitrijević BB. Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. in World Journal of Gastroenterology. 2007;13(8):1187-1194.
doi:10.3748/wjg.v13.i8.1187 .
Krtolica-Žikić, Koviljka, Krajnović, Milena M., Usaj-Knežević, Slavica, Babić, Dragan, Jovanovic, Dusan, Dimitrijević, Bogomir B., "Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value" in World Journal of Gastroenterology, 13, no. 8 (2007):1187-1194,
https://doi.org/10.3748/wjg.v13.i8.1187 . .
36
40
43

Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease

Stanojević, Boban; Lohse, P.; Neskovic, G. G.; Damjanovic, S. M.; Novkovic, T. B.; Jovanović-Ćupić, Snežana P.; Dimitrijević, Bogomir B.

(2007)

TY  - JOUR
AU  - Stanojević, Boban
AU  - Lohse, P.
AU  - Neskovic, G. G.
AU  - Damjanovic, S. M.
AU  - Novkovic, T. B.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3319
AB  - Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited cancer predisposition syndrome due to germline mutations in the VHL tumor suppressor gene which is associated with virtually complete penetrance. The VHL syndrome has a highly variable phenotypic expressivity including retinal and CNS haemanioblastomas, pheochromocytomas, renal clear cell carcinomas, and multifocal cysts. In order to establish VHL gene testing, we analyzed three families affected by VHL disease, using SSCP mutation screening and DNA sequencing. Among 18 family members with and without clinical manifestations, eight cases with germline VHL mutations were detected. In family A, a c.490G GT T/ p.Gly93Cys substitution was found. In family 13, with pheochromocytoma only phenotype, we detected a previously not described c.463G GT A/p.Val84Met replacement. Within this family, a prenatal diagnosis was also performed. Affected members of the third family with a VHL type I disease carried a c.475T GT C/p.Trp88Arg exchange. All these mutations were located in exon 1 of the VHL tumor suppressor gene. Alterations in this hydrophobic region of the core beta domain of the VHL protein are known to have a variety of phenotypic consequences. We observed also intrafamiliar variation in time of onset and severity of the disease.
T2  - Neoplasma
T1  - Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease
VL  - 54
IS  - 5
SP  - 402
EP  - 406
ER  - 
@article{
author = "Stanojević, Boban and Lohse, P. and Neskovic, G. G. and Damjanovic, S. M. and Novkovic, T. B. and Jovanović-Ćupić, Snežana P. and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited cancer predisposition syndrome due to germline mutations in the VHL tumor suppressor gene which is associated with virtually complete penetrance. The VHL syndrome has a highly variable phenotypic expressivity including retinal and CNS haemanioblastomas, pheochromocytomas, renal clear cell carcinomas, and multifocal cysts. In order to establish VHL gene testing, we analyzed three families affected by VHL disease, using SSCP mutation screening and DNA sequencing. Among 18 family members with and without clinical manifestations, eight cases with germline VHL mutations were detected. In family A, a c.490G GT T/ p.Gly93Cys substitution was found. In family 13, with pheochromocytoma only phenotype, we detected a previously not described c.463G GT A/p.Val84Met replacement. Within this family, a prenatal diagnosis was also performed. Affected members of the third family with a VHL type I disease carried a c.475T GT C/p.Trp88Arg exchange. All these mutations were located in exon 1 of the VHL tumor suppressor gene. Alterations in this hydrophobic region of the core beta domain of the VHL protein are known to have a variety of phenotypic consequences. We observed also intrafamiliar variation in time of onset and severity of the disease.",
journal = "Neoplasma",
title = "Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease",
volume = "54",
number = "5",
pages = "402-406"
}
Stanojević, B., Lohse, P., Neskovic, G. G., Damjanovic, S. M., Novkovic, T. B., Jovanović-Ćupić, S. P.,& Dimitrijević, B. B.. (2007). Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease. in Neoplasma, 54(5), 402-406.
Stanojević B, Lohse P, Neskovic GG, Damjanovic SM, Novkovic TB, Jovanović-Ćupić SP, Dimitrijević BB. Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease. in Neoplasma. 2007;54(5):402-406..
Stanojević, Boban, Lohse, P., Neskovic, G. G., Damjanovic, S. M., Novkovic, T. B., Jovanović-Ćupić, Snežana P., Dimitrijević, Bogomir B., "Germline VHL gene mutations in three Serbian families with von Hippel-Lindau disease" in Neoplasma, 54, no. 5 (2007):402-406.
1

Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.

Mandušić, Vesna; Krtolica-Žikić, Koviljka; Nikolic-Vukosavljevic, Dragica; Popov-Celeketic, D.; Plećaš, D.; Boricic, I.; Dimitrijević, Bogomir B.; Tanić, Nikola

(2007)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Krtolica-Žikić, Koviljka
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Popov-Celeketic, D.
AU  - Plećaš, D.
AU  - Boricic, I.
AU  - Dimitrijević, Bogomir B.
AU  - Tanić, Nikola
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3414
T2  - Archives of biological sciences
T1  - Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.
VL  - 59
IS  - 2
SP  - 15P
EP  - 16P
DO  - 10.2298/ABS070215PM
ER  - 
@article{
author = "Mandušić, Vesna and Krtolica-Žikić, Koviljka and Nikolic-Vukosavljevic, Dragica and Popov-Celeketic, D. and Plećaš, D. and Boricic, I. and Dimitrijević, Bogomir B. and Tanić, Nikola",
year = "2007",
journal = "Archives of biological sciences",
title = "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.",
volume = "59",
number = "2",
pages = "15P-16P",
doi = "10.2298/ABS070215PM"
}
Mandušić, V., Krtolica-Žikić, K., Nikolic-Vukosavljevic, D., Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, B. B.,& Tanić, N.. (2007). Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of biological sciences, 59(2), 15P-16P.
https://doi.org/10.2298/ABS070215PM
Mandušić V, Krtolica-Žikić K, Nikolic-Vukosavljevic D, Popov-Celeketic D, Plećaš D, Boricic I, Dimitrijević BB, Tanić N. Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of biological sciences. 2007;59(2):15P-16P.
doi:10.2298/ABS070215PM .
Mandušić, Vesna, Krtolica-Žikić, Koviljka, Nikolic-Vukosavljevic, Dragica, Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, Bogomir B., Tanić, Nikola, "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues." in Archives of biological sciences, 59, no. 2 (2007):15P-16P,
https://doi.org/10.2298/ABS070215PM . .

Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance

Nikolic-Vukosavljevic, D.; Mandušić, Vesna; Nešković-Konstantinović, Zora; Dimitrijević, Bogomir B.

(2007)

TY  - CONF
AU  - Nikolic-Vukosavljevic, D.
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3479
C3  - Breast
T1  - Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance
VL  - 16
SP  - S13
EP  - S14
DO  - 10.1016/S0960-9776(07)70069-3
ER  - 
@conference{
author = "Nikolic-Vukosavljevic, D. and Mandušić, Vesna and Nešković-Konstantinović, Zora and Dimitrijević, Bogomir B.",
year = "2007",
journal = "Breast",
title = "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance",
volume = "16",
pages = "S13-S14",
doi = "10.1016/S0960-9776(07)70069-3"
}
Nikolic-Vukosavljevic, D., Mandušić, V., Nešković-Konstantinović, Z.,& Dimitrijević, B. B.. (2007). Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast, 16, S13-S14.
https://doi.org/10.1016/S0960-9776(07)70069-3
Nikolic-Vukosavljevic D, Mandušić V, Nešković-Konstantinović Z, Dimitrijević BB. Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast. 2007;16:S13-S14.
doi:10.1016/S0960-9776(07)70069-3 .
Nikolic-Vukosavljevic, D., Mandušić, Vesna, Nešković-Konstantinović, Zora, Dimitrijević, Bogomir B., "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance" in Breast, 16 (2007):S13-S14,
https://doi.org/10.1016/S0960-9776(07)70069-3 . .

Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients

Ivanović, Vesna; Demajo, Miroslav; Krtolica-Žikić, Koviljka; Krajnović, Milena M.; Dimitrijević, Bogomir B.; Konstantinovic, M.; Baltic, Vladimir; Prtenjak, Gordana; Stojiljković, Bratislav; Breberina, Milan; Nešković-Konstantinović, Zora; Nikolic-Vukosavljevic, Dragica

(2006)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Konstantinovic, M.
AU  - Baltic, Vladimir
AU  - Prtenjak, Gordana
AU  - Stojiljković, Bratislav
AU  - Breberina, Milan
AU  - Nešković-Konstantinović, Zora
AU  - Nikolic-Vukosavljevic, Dragica
PY  - 2006
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3079
AB  - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
T2  - Clinica Chimica Acta
T1  - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
VL  - 371
IS  - 1-2
SP  - 191
EP  - 193
DO  - 10.1016/j.cca.2006.02.027
ER  - 
@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltic, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolic-Vukosavljevic, Dragica",
year = "2006",
abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.",
journal = "Clinica Chimica Acta",
title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients",
volume = "371",
number = "1-2",
pages = "191-193",
doi = "10.1016/j.cca.2006.02.027"
}
Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltic, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolic-Vukosavljevic, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193.
https://doi.org/10.1016/j.cca.2006.02.027
Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltic V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolic-Vukosavljevic D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193.
doi:10.1016/j.cca.2006.02.027 .
Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltic, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolic-Vukosavljevic, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193,
https://doi.org/10.1016/j.cca.2006.02.027 . .
50
54
56